Alector, Inc. (ALEC)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$1.830.00%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Alector, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	4.81M
EPS	—	0.218
Annual ending 2026-12-31
Revenue	—	12.57M
EPS	—	-0.382
Annual ending 2027-12-31
Revenue	—	13.3M
EPS	—	-0.836

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain cash runway through 2027	The company plans to keep enough cash to operate through 2027.	Intact	Cash runway falls short of 2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 2 of 2 supplied transcript quarters. Cash, cash equivalents, and investments were $206.5 million in 2026-Q1 and $172.8 million in 2026-Q2; management repeated its runway statement through 2027. Runway remains the stated commitment, but the reported cash balance declined and no updated runway extension is stated in these quarters, indicating limited progress against the stated horizon. Delivery assessment Oct 24, 2026
Reduce losses and improve earnings	A supporting condition in Alector, Inc.'s published investment case. The stated target is EPS loss narrows toward -$0.7 in 2027.	Improving	EPS loss worsens beyond -$0.88 in 2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue reaches about $15.5 million in 2025	Alector aims to grow revenue to about $15.5 million in 2025.	Improving	Revenue falls below ~$13 million in 2025	Revenue: $3.32M FY2026-Q2; GAAP. Published target: ~$15.5 million. Target period ends 2025-12-31; this observation covers 2026-Q2. Source published Aug 6, 20263,320,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: f49e7d67-b57e-4d21-a3b4-022b5cb540d9. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.84

$-0.70 → $-0.84 · observed estimates

FY2027 revenue$0.01B

$0.02B → $0.01B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.70	$22,881,500	7 / 8
2026-07-25	$-0.70	$22,881,500	7 / 8
2026-07-26	$-0.70	$22,881,500	7 / 8
2026-07-27	$-0.70	$22,881,500	7 / 8
2026-07-28	$-0.70	$22,881,500	7 / 8
2026-07-29	$-0.70	$22,881,500	7 / 8
2026-07-30	$-0.70	$22,881,500	7 / 8
2026-07-31	$-0.70	$22,881,500	7 / 8
2026-08-01	$-0.70	$22,881,500	7 / 8
2026-08-02	$-0.70	$22,881,500	7 / 8
2026-08-03	$-0.70	$22,881,500	7 / 8
2026-08-04	$-0.70	$22,881,500	7 / 8
2026-08-05	$-0.70	$22,881,500	7 / 8
2026-08-06	$-0.70	$22,881,500	7 / 8
2026-08-07	$-0.60	$30,508,667	6 / 6
2026-08-08	$-0.70	$22,881,500	7 / 8
2026-08-09	$-0.70	$22,881,500	7 / 8
2026-08-10	$-0.70	$22,881,500	7 / 8
2026-08-11	$-0.60	$30,508,667	6 / 6
2026-08-12	$-0.74	$27,449,710	7 / 7
2026-08-13	$-0.74	$27,449,710	7 / 7
2026-08-14	$-0.60	$30,508,667	6 / 6
2026-08-15	$-0.60	$30,508,667	6 / 5
2026-08-16	$-0.60	$30,508,667	6 / 6
2026-08-17	$-0.60	$30,508,667	6 / 6
2026-08-18	$-0.60	$30,508,667	6 / 6
2026-08-19	$-0.60	$30,508,667	6 / 6
2026-08-20	$-0.60	$30,508,667	6 / 6
2026-08-21	$-0.70	$34,890,000	6 / 6
2026-08-22	$-0.70	$34,890,000	6 / 6
2026-08-23	$-0.70	$34,890,000	6 / 6
2026-08-24	$-0.70	$34,890,000	6 / 6
2026-08-25	$-0.70	$34,890,000	6 / 6
2026-08-26	$-0.70	$34,890,000	6 / 6
2026-08-27	$-0.70	$34,890,000	6 / 6
2026-08-28	$-0.70	$34,890,000	6 / 6
2026-08-29	$-0.70	$34,890,000	6 / 6
2026-08-30	$-0.70	$34,890,000	6 / 6
2026-08-31	$-0.70	$34,890,000	6 / 6
2026-09-01	$-0.70	$34,890,000	6 / 6
2026-09-02	$-0.70	$34,890,000	6 / 6
2026-09-03	$-0.70	$34,890,000	6 / 6
2026-09-04	$-0.70	$34,890,000	6 / 6
2026-09-05	$-0.70	$34,890,000	6 / 6
2026-09-06	$-0.70	$34,890,000	6 / 6
2026-09-07	$-0.70	$34,890,000	6 / 6
2026-09-08	$-0.70	$34,890,000	6 / 6
2026-09-09	$-0.70	$34,890,000	6 / 6
2026-09-10	$-0.70	$34,890,000	6 / 6
2026-09-11	$-0.70	$34,890,000	6 / 6
2026-09-12	$-0.70	$34,890,000	6 / 6
2026-09-13	$-0.70	$34,890,000	6 / 6
2026-09-14	$-0.70	$34,890,000	6 / 6
2026-09-15	$-0.70	$34,890,000	6 / 6
2026-09-16	$-0.70	$34,890,000	6 / 6
2026-09-17	$-0.70	$34,890,000	6 / 6
2026-09-18	$-0.70	$34,890,000	6 / 6
2026-09-19	$-0.70	$34,890,000	6 / 6
2026-09-20	$-0.70	$34,890,000	6 / 6
2026-09-21	$-0.70	$34,890,000	6 / 6
2026-09-22	$-0.70	$34,890,000	6 / 6
2026-09-23	$-0.70	$34,890,000	6 / 6
2026-09-24	$-0.70	$34,890,000	6 / 6
2026-09-25	$-0.67	$39,212,000	6 / 5
2026-09-26	$-0.67	$39,212,000	6 / 5
2026-09-27	$-0.67	$39,212,000	5 / 5
2026-09-28	$-0.67	$39,212,000	5 / 5
2026-09-29	$-0.67	$39,212,000	5 / 5
2026-09-30	$-0.67	$39,212,000	5 / 5
2026-10-01	$-0.67	$39,212,000	5 / 5
2026-10-02	$-0.67	$39,212,000	5 / 5
2026-10-03	$-0.67	$39,212,000	5 / 5
2026-10-04	$-0.67	$39,212,000	5 / 5
2026-10-05	$-0.67	$39,212,000	5 / 5
2026-10-06	$-0.67	$39,212,000	5 / 5
2026-10-07	$-0.68	Unavailable	5 / 4
2026-10-08	$-0.68	$33,796,667	5 / 5
2026-10-09	$-0.68	$33,796,667	5 / 5
2026-10-10	$-0.68	$33,796,667	5 / 5
2026-10-11	$-0.68	$33,796,667	5 / 5
2026-10-12	$-0.68	$33,796,667	5 / 5
2026-10-13	$-0.68	$33,796,667	5 / 5
2026-10-14	$-0.68	$33,796,667	5 / 5
2026-10-15	$-0.84	$13,296,667	5 / 5
2026-10-16	$-0.84	$13,296,667	5 / 5
2026-10-17	$-0.84	$13,296,667	5 / 5
2026-10-18	$-0.84	$13,296,667	5 / 5
2026-10-19	$-0.84	$13,296,667	5 / 5
2026-10-20	$-0.84	$13,296,667	5 / 5
2026-10-21	$-0.84	$13,296,667	5 / 5
2026-10-22	$-0.84	$13,296,667	5 / 5
2026-10-23	$-0.84	$13,296,667	5 / 5
2026-10-24	$-0.84	$13,296,667	5 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	3	3	2
2026-06-01	3	3	2
2026-07-01	3	3	2
2026-08-01	3	3	2
2026-09-01	3	3	2
2026-10-01	3	2	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 3 Buy / Strong Buy · 2 Hold · 2 Sell / Strong Sell

0 upgrades0 downgrades3 maintains

Recent actions · Sep 25–Oct 24 · 3 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

UBSOct 6

$1.50New observation · no comparable prior

Morgan StanleyOct 6 · prior May 4

$2.00 → $3.00+50.0%

$0$1.65$3.30

1 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain cash runway through 2027Direct metric needs a verified mapping
Reduce losses and improve earningsDirect metric needs a verified mapping
Revenue reaches about $15.5 million in 2025Revenue: $3.32M

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.3%Typical daily move · historical

Downside history

-48.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Alector, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

ALEC is a speculative, loss-making biotechnology company whose longer-term case depends on advancing its pipeline. The thesis is intact, but its signal recently shifted from mildly favorable to mixed, and evidence of substantive pipeline delivery remains limited.

What's priced into Alector, Inc.

The valuation is tagged as stretched, with a durable premium versus peers and medium model confidence. This suggests the market already assumes a meaningful degree of lasting business value, leaving less room for execution to fall short of expectations.

What the fundamentals likely do

Near term, expense reductions are real, but cash declined between the first and second quarters of 2026, while collaboration revenue was lower than a year earlier. Management says cash runway extends through 2027 and is targeting an AL137 IND submission in Q1 2027, but no clinical milestone completion is reported; the next guidance and a high-miss-rate industry add risk.

What Alector, Inc. hinges on

The multi-year case hinges on turning the stated pipeline focus into clinical progress while maintaining the stated cash runway. Near term, a guidance cut or further weakening in jobs data could weigh on the business outlook, while continued strong results from healthcare sector bellwethers would support a more favorable sector backdrop.